Welcome to our dedicated page for Kenvue SEC filings (Ticker: KVUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kenvue Inc.’s filings tell a story that reaches far beyond pain-relief sales and skincare ads. Inside each 10-K, investors uncover how royalty agreements with Johnson & Johnson affect margins, how product-liability reserves are set for talc and acetaminophen, and how global supply chains drive costs across Tylenol, Listerine and Aveeno. If you have ever searched for “Kenvue SEC filings explained simply,” this page is built for you.
Stock Titan combines real-time EDGAR feeds with AI-powered summaries, turning dense documents into clear insights. Whether you need the latest Kenvue quarterly earnings report 10-Q filing or a quick alert on Kenvue Form 4 insider transactions real-time, our platform delivers context in minutes, not hours. Want to explore compensation? The Kenvue proxy statement executive compensation section is parsed so you can see how management incentives align with brand growth.
Here’s what professionals track on this page:
- Kenvue insider trading Form 4 transactions to monitor executive stock moves
- Kenvue 8-K material events explained for recall notices or strategic updates
- Kenvue annual report 10-K simplified to understand segment revenue and litigation risk
- Understanding Kenvue SEC documents with AI for faster due-diligence
- Kenvue earnings report filing analysis that compares quarter-over-quarter progress
All filings—10-K, 10-Q, 8-K, S-8, and every Kenvue executive stock transactions Form 4—arrive the moment they hit EDGAR. Our expert models surface key numbers, flag unusual language, and link each disclosure to the brands that drive value. Research the company behind your medicine cabinet with confidence.
T. Rowe Price Associates, Inc. reports beneficial ownership of 168,318,661 shares of Kenvue Inc. common stock, equal to 8.8% of the class, in a Schedule 13G filing (Amendment No. 4). The filing shows sole voting power over 158,120,414 shares and sole dispositive power over 168,041,407 shares, and explicitly states the holdings are held in the ordinary course of business and not for the purpose of changing control.
The document identifies the issuer (CUSIP 49177J102), provides the issuer address for Kenvue, lists T. Rowe Price Associates, Inc. as the reporting person (Maryland), and is signed by Ellen York, Vice President, dated 08/14/2025 with the reportable event date of 06/30/2025.
Event: On August 7, 2025, Kenvue Inc. (KVUE) furnished a Current Report on Form 8-K announcing that it issued a press release (Exhibit 99.1) reporting its financial results for the fiscal second quarter ended June 29, 2025.
Disclosure status and exhibits: The filing states the information is furnished, not filed, and therefore is not subject to Section 18 liability or incorporated by reference except by specific reference. The filing attaches Exhibit 99.1 (press release dated August 7, 2025) and Exhibit 104 (cover page in Inline XBRL). The report is signed by CFO Amit Banati on August 7, 2025.
On 14 July 2025, Kenvue Inc. (NYSE: KVUE) filed a Form 8-K disclosing three material items.
Item 2.02 – Preliminary Q2 results: A press release (Exhibit 99.1) announced select, unaudited second-quarter figures; no numbers appear in the filing. Full Q2 results and updated FY-25 guidance are scheduled for 7 Aug 2025.
Item 5.02 – Leadership change: CEO Thibaut Mongon resigned from both the CEO post and the Board effective 14 Jul 2025, qualifying for standard severance and “retirement” equity treatment. The Board appointed independent director Kirk L. Perry as interim CEO. His offer letter (Exhibit 10.1) provides (i) $1.25 million annual salary, (ii) up to $1.5 million performance-based cash award payable when a permanent CEO is installed, (iii) $5 million in equity (50% stock options, 50% RSUs) vesting after one year, and (iv) up to $25,000 legal-fee reimbursement. Perry will not join the Severance Plan and will receive no additional Board fees.
Item 8.01 – Strategic review: The Board formed a five-member Strategic Review Committee, chaired by Melanie L. Healey and advised by Centerview Partners and McKinsey & Co., to evaluate alternatives such as brand-portfolio optimization aimed at accelerating profitable growth and “unlocking inherent value.” No timeline or specific options were disclosed.
The filing includes standard forward-looking disclaimers and lists three exhibits: the offer letter, the press release, and the Inline XBRL cover page.
Investor takeaway: The sudden CEO departure injects uncertainty, yet the swift appointment of an experienced interim leader and initiation of a strategic review indicate proactive Board engagement. More clarity should emerge with Q2 earnings on 7 Aug 2025.
FAQ
What is the current stock price of Kenvue (KVUE)?
What is the market cap of Kenvue (KVUE)?
